GILD vs. QGEN: Gilead Sciences vs. Qiagen Stock Comparison

Company Profile

Gilead Sciences (GILD) and Qiagen (QGEN) both fall under the Pharmaceuticals, Biotechnology & Life Sciences industry group, but GILD is classified in Biotechnology while QGEN is classified in Life Sciences Tools & Services.

Price Performance

Cumulative Growth

Trailing Returns

Calendar-Year Returns

Performance Metrics

Risk Profile

Drawdown History

Return Distribution

Risk Metrics

Risk-Adjusted Performance

Risk-Return Positioning

Risk-Adjusted Metrics

Profitability

Gilead Sciences (GILD) reports a negative ROE of -22.45%; negative ROE can reflect losses or negative shareholders’ equity, so it is harder to read as capital efficiency. Meanwhile Qiagen (QGEN) reports 10.81%, ranking against industry peers normally.

Gilead Sciences (GILD) reports a negative net margin of -12.46%, usually indicating a net loss over the period. Meanwhile Qiagen (QGEN) reports 18.20%, ranking against industry peers normally.

Both Gilead Sciences (GILD) at 42.43% and Qiagen (QGEN) at 27.75% convert sales into operating profit at a top-quartile rate, pointing to tighter cost discipline before financing and tax.

Profitability Metrics

Growth

Both Gilead Sciences (GILD) at 2.39% and Qiagen (QGEN) at 5.65% land near their industries' usual revenue growth ranges, so top-line momentum looks broadly in line with peers on both sides.

Both Gilead Sciences (GILD) at 1,684.21% and Qiagen (QGEN) at 409.76% grew per-share earnings faster than their entire industry benchmark ranges for EPS growth — a strong showing on both sides, though a depressed base year can exaggerate the percentage, so the level of earnings matters too.

Growth Metrics

Financial Strength

Qiagen (QGEN) at 2.63 keeps current ratio within its industry’s typical mid-range, while Gilead Sciences (GILD) at 1.38 runs in the tighter-liquidity quartile — a thinner cushion against current liabilities for GILD.

Qiagen (QGEN) at 0.47 is near its industry mid-range for debt-to-equity ratio, while Gilead Sciences (GILD) at 2.02 sits above its benchmark range, pointing to a heavier debt load relative to equity.

Financial Strength Metrics

Dividends

Both Gilead Sciences (GILD) at 1.94% and Qiagen (QGEN) at 0.71% yield above their industries’ entire benchmark ranges — high enough that dividend safety, not income, becomes the first question.

Both Gilead Sciences (GILD) at 43.46% and Qiagen (QGEN) at 18.21% pay out more of their earnings than any of their industry peers — the thinnest cover in their groups, so dividend headroom deserves attention.

Dividend Metrics

Valuation

An earnings multiple is available for just one side: Qiagen (QGEN) trades at 27.21 times trailing earnings, ranked against its peers, while Gilead Sciences (GILD) has no P/E ratio this period.

On P/S ratio, both Gilead Sciences (GILD) at 6.68 and Qiagen (QGEN) at 4.91 are priced roughly in line with their industries — neither looks cheap nor rich on a sales basis.

Qiagen (QGEN) at 2.99 sits near its industry’s typical P/B ratio, while Gilead Sciences (GILD) at 15.88 prices above its benchmark range — GILD looks rich relative to book.

Valuation Metrics